Erfonrilimab is under clinical development by Alphamab Oncology and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase II drugs for Metastatic Hepatocellular Carcinoma (HCC) have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Erfonrilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Erfonrilimab overview

KN-046 is under development for the treatment of solid tumors including metastatic esophageal squamous cell carcinoma, metastatic nasopharangeal, thymic carcinoma, urothelial cancer, HNSCC, multiple myeloma, SCLC, melanoma, RCC, hepatocellular carcinoma, gastric cancer, gastroesophageal (GE) junction carcinoma, locally advanced or metastatic pancreatic ductal adenocarcinoma, adenocarcinoma of the gastroesophageal junction, metastatic triple negative breast cancer, non-squamous non-small cell lung cancer, pancreatic cancer, squamous non-small cell lung cancer, colorectal cancer and lymphomas and cholangiocarcinoma. The drug candidate is administered intravenously. The therapeutic candidate is a bi-specific monoclonal antibody and it is developed based on CRIB (charge repulsion induced bi-specificity) technology that is used to generate multi-fuctional antibodies or fusion proteins. It is an immunomodulator. I acts by targeting PD L1 and CTLA-4. It was also under development for biliary tract cancer and pancreatic ductal adenocarcinoma.

Alphamab Oncology overview

Alphamab Oncology (Alphamab) is a clinical-stage biopharmaceutical company that discovers, develops, manufactures and commercializes therapeutics for the treatment of cancer. The company’s pipeline products include KN035; an injectable PD-L1 inhibitor for the treatment of dMMR and MSI-H solid tumors, KN046; a BsAb immune checkpoint inhibitor, KN026; an anti-HER2 bispecific antibody. It also comprises KN019; a CTLA-4-based immunosuppressant fusion protein drug candidate used for treating indications such as autoimmune diseases and induced immune disorders. Alphamab offers JSKN-003, JSKN-001, JSKN-002, JSKN-004, JSKN-005, JSKN-006 and JSKN-008. The company appears its proprietary CRIB and CRAM platforms for bispecific and protein engineering and antibody screening to best-in-class medicines in oncology. Alphamab is headquartered in Suzhou, Jiangsu, China.

For a complete picture of Erfonrilimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.